MX2023002377A - Vacuna contra el citomegalovirus humano. - Google Patents

Vacuna contra el citomegalovirus humano.

Info

Publication number
MX2023002377A
MX2023002377A MX2023002377A MX2023002377A MX2023002377A MX 2023002377 A MX2023002377 A MX 2023002377A MX 2023002377 A MX2023002377 A MX 2023002377A MX 2023002377 A MX2023002377 A MX 2023002377A MX 2023002377 A MX2023002377 A MX 2023002377A
Authority
MX
Mexico
Prior art keywords
human cytomegalovirus
cytomegalovirus vaccine
vaccine
hcmv
antigen
Prior art date
Application number
MX2023002377A
Other languages
English (en)
Inventor
Andrea Carfi
Shinu John
Kimberly Hassett
Jack F Kramarczyk
Phil White
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MX2023002377A publication Critical patent/MX2023002377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect

Abstract

Los aspectos de la divulgación se relacionan con métodos para producir una respuesta inmunitaria específica de antígeno al citomegalovirus humano (hCMV) en un sujeto mediante la administración de 5 vacunas de ARNm.
MX2023002377A 2020-08-25 2021-08-25 Vacuna contra el citomegalovirus humano. MX2023002377A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063070134P 2020-08-25 2020-08-25
US202063079421P 2020-09-16 2020-09-16
US202163136117P 2021-01-11 2021-01-11
PCT/US2021/047541 WO2022046898A1 (en) 2020-08-25 2021-08-25 Human cytomegalovirus vaccine

Publications (1)

Publication Number Publication Date
MX2023002377A true MX2023002377A (es) 2023-05-22

Family

ID=80353887

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002377A MX2023002377A (es) 2020-08-25 2021-08-25 Vacuna contra el citomegalovirus humano.

Country Status (12)

Country Link
US (1) US20220401551A1 (es)
EP (1) EP4204001A1 (es)
JP (1) JP2023540476A (es)
KR (1) KR20230057403A (es)
CN (1) CN116234570A (es)
AU (1) AU2021331064A1 (es)
BR (1) BR112023003009A2 (es)
CA (1) CA3193042A1 (es)
IL (1) IL300739A (es)
MX (1) MX2023002377A (es)
TW (1) TW202228771A (es)
WO (1) WO2022046898A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
WO2023212696A1 (en) 2022-04-29 2023-11-02 Modernatx, Inc. Lyophilized human cytomegalovirus vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070613A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
MA46584A (fr) * 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
EP4028030A4 (en) * 2019-09-11 2023-09-27 ModernaTX, Inc. VACCINE AGAINST HUMAN CYTOMEGALOVIRUS

Also Published As

Publication number Publication date
CA3193042A1 (en) 2022-03-03
EP4204001A1 (en) 2023-07-05
BR112023003009A2 (pt) 2023-04-25
IL300739A (en) 2023-04-01
CN116234570A (zh) 2023-06-06
AU2021331064A1 (en) 2023-03-16
JP2023540476A (ja) 2023-09-25
KR20230057403A (ko) 2023-04-28
TW202228771A (zh) 2022-08-01
US20220401551A1 (en) 2022-12-22
WO2022046898A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2023002377A (es) Vacuna contra el citomegalovirus humano.
MX2020007675A (es) Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante.
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
MX2020012144A (es) Composicion de vacuna.
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
WO2009025770A3 (en) A heterologous prime-boost immunization regimen
MX345704B (es) Vacuna bovinas y métodos.
MX363529B (es) Vesículas de membrana externa.
PH12015500956B1 (en) Novel mucosal adjuvants and delivery systems
MX2013003470A (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
EP3908315A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSE TO VACCINATION AND ENHANCING VACCINE PRODUCTION
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
PH12016502529A1 (en) Influenza vaccine nasal vaccination system
MX2015014005A (es) Complejo inmunogenico para vacunacion y metodo de obtencion.
MX2022004869A (es) Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.
WO2012103510A8 (en) Advanced prime and boost vacinne
EP3784250A4 (en) METHODS OF ENHANCING THE IMMUNOGENICITY OF WEAKLY IMMUNOGENIC ANTIGEN-SPECIFIC VACCINES USING ORAL YEAST BETA-GLUCANS
MX2016005434A (es) Microparticulas de almidon crudo como adyuvante en vacunas.